<DOC>
	<DOCNO>NCT01162187</DOCNO>
	<brief_summary>All contemporary guideline secondary prevention acute coronary syndrome recommend combination aspirin , beta-blockers , ACE-inhibitors statin . Yet underutilisation drug common . We know detail drive underutilisation , long term consequence survival discharge hospital . Also unknown whether potential adverse effect underutilisation individual secondary prevention drug . This study assess impact secondary prevention underutilisation survival .</brief_summary>
	<brief_title>Secondary Prevention Acute Coronary Syndromes : A CALIBER Study</brief_title>
	<detailed_description>Using information England Wales audit acute coronary syndrome ( Myocardial Ischaemia National Audit Project ( MINAP ) ) aim ass : ( ) Survival first time MINAP-registered event death function secondary prevention medication : To degree effect medication ( assume equal , independent additive ) relate patient survival ? Is evidence differential effect discharge medication ? ( ii ) ( ) Survival first time MINAP-registered event death second time MINAP-registered event function secondary prevention medication : To degree effect medication ( assume equal , independent additive ) relate compete risk ? Is evidence differential effect discharge medication ? ( b ) Survival first time MINAP-registered event death second time MINAP-registered phenotyped STEMI , NSTEMI Unstable Angina . To degree effect medication ( assume equal , independent additive ) relate compete risk ? Is evidence differential effect discharge medication ? ( iii ) What impact would ensure medication take event free survival ? This study part CALIBER ( Cardiovascular disease research use link bespoke study electronic record ) programme fund 5 year NIHR Wellcome Trust . The central theme CALIBER research linkage Myocardial Ischaemia National Audit Project ( MINAP ) primary care ( GPRD ) resource . The overarch aim CALIBER good understand aetiology prognosis specific coronary phenotype across range causal domain , particularly electronic record provide contribution beyond traditional study . CALIBER receive Ethics approval ( ref 09/H0810/16 ) ECC approval ( ref ECC 2-06 ( b ) /2009 CALIBER dataset ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>Individuals Acute Coronary Syndrome register MINAP database .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>secondary prevention</keyword>
	<keyword>aspirin</keyword>
	<keyword>beta blocker</keyword>
	<keyword>ACE inhibitor</keyword>
	<keyword>statin</keyword>
	<keyword>acute coronary syndrome</keyword>
	<keyword>myocardial infarction</keyword>
	<keyword>unstable angina</keyword>
	<keyword>trend</keyword>
</DOC>